$STEK
Stemtech Corp Stock $stek

$stek Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000168316822008016 Filed on November 23, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$1.080M	$1.047M	$907.9K
YoY Change	-17.74%	15.33%
Cost Of Revenue	$327.6K	$180.6K	$126.4K
YoY Change	-26.78%	42.85%
Gross Profit	$752.0K	$866.4K	$781.4K
YoY Change	-13.07%	10.88%
Gross Profit Margin	69.66%	82.75%	86.07%
Selling, General & Admin	$898.2K	$3.943M	$1.384M
YoY Change	-56.11%	184.93%
% of Gross Profit	119.44%	455.04%	177.07%
Research & Development		$0.00
YoY Change
% of Gross Profit		0.0%
Depreciation & Amortization	$117.2K	$113.5K	$324.2K
YoY Change	12.32%	-65.01%
% of Gross Profit	15.59%	13.09%	41.49%
Operating Expenses	$1.184M	$4.249M	$1.517M
YoY Change	-55.91%	180.05%
Operating Profit	-$432.2K	-$3.382M	-$735.8K
YoY Change	-76.27%	359.72%
Interest Expense	-$204.2K	$16.40M	-$4.612M
YoY Change	-119.3%	-455.46%
% of Operating Profit
Other Income/Expense, Net	$600.00	$20.77M	$28.48K
YoY Change	-100.71%	72823.58%
Pretax Income	-$446.1K	$17.39M	-$5.320M
YoY Change	-47.4%	-426.83%
Income Tax	$95.62K
% Of Pretax Income
Net Earnings	-$518.9K	$17.42M	-$5.309M
YoY Change	-38.19%	-428.04%
Net Earnings / Revenue	-48.06%	1663.46%	-584.83%
Basic Earnings Per Share		$0.38	-$0.28
Diluted Earnings Per Share	-$0.01	$0.38	-$277.9K
COMMON SHARES
Basic Shares Outstanding	48.63M shares	44.80M shares	19.10M shares
Diluted Shares Outstanding		45.59M shares	19.10M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.5K	$123.1K	$1.598M
YoY Change	-84.0%	-92.3%
Cash & Equivalents	$132.5K	$123.1K	$1.598M
Short-Term Investments
Other Short-Term Assets	$287.1K	$255.1K	$372.1K
YoY Change	-11.59%	-31.46%
Inventory	$158.1K	$181.8K	$158.7K
Prepaid Expenses
Receivables	$34.77K	$39.75K	$12.14K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$612.4K	$599.7K	$2.141M
YoY Change	-61.73%	-71.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.30K	$30.70K	$106.2K
YoY Change	-17.7%	-71.09%
Goodwill	$467.4K	$467.4K
YoY Change	0.0%
Intangibles	$2.994M	$3.097M
YoY Change	-12.11%
Long-Term Investments	$23.07K	$28.42K	$44.04K
YoY Change	-40.37%	-35.47%
Other Assets			$8.050K
YoY Change
Total Long-Term Assets	$3.655M	$3.751M	$4.135M
YoY Change	-11.3%	-9.29%
TOTAL ASSETS
Total Short-Term Assets	$612.4K	$599.7K	$2.141M
Total Long-Term Assets	$3.655M	$3.751M	$4.135M
Total Assets	$4.267M	$4.351M	$6.276M
YoY Change	-25.4%	-30.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.397M	$3.868M	$2.744M
YoY Change	-16.15%	40.99%
Accrued Expenses	$119.1K	$62.02K	$475.4K
YoY Change	113.58%	-86.95%
Deferred Revenue
YoY Change
Short-Term Debt	$1.143M	$1.631M	$657.5K
YoY Change	8.28%	148.15%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.416M	$8.995M	$6.462M
YoY Change	-21.0%	39.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$276.1K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$23.07K	$71.55K	$3.971M
YoY Change	-80.62%	-98.2%
Total Long-Term Liabilities	$23.07K	$71.55K	$4.247M
YoY Change	-93.19%	-98.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.416M	$8.995M	$6.462M
Total Long-Term Liabilities	$23.07K	$71.55K	$4.247M
Total Liabilities	$7.439M	$9.067M	$10.07M
YoY Change	-23.51%	-9.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.63M	-$21.11M
YoY Change	65.3%
Common Stock	$19.44M	$48.63K
YoY Change	91.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.434M	-$4.001M	-$3.792M
YoY Change
Total Liabilities & Shareholders Equity	$4.267M	$4.351M	$6.276M
YoY Change	-25.4%	-30.68%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$518.9K	$17.42M	-$5.309M
YoY Change	-38.19%	-428.04%
Depreciation, Depletion And Amortization	$117.2K	$113.5K	$324.2K
YoY Change	12.32%	-65.01%
Cash From Operating Activities	-$240.8K	-$231.4K	-$757.0K
YoY Change	-77.5%	-69.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$880.00
YoY Change
Cash From Investing Activities			$880.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-176.0K	361.1K	2.019M
YoY Change	-133.56%	-82.12%
NET CHANGE
Cash From Operating Activities	-240.8K	-231.4K	-757.0K
Cash From Investing Activities			880.0
Cash From Financing Activities	-176.0K	361.1K	2.019M
Net Change In Cash	-416.8K	129.7K	1.263M
YoY Change	-23.8%	-89.73%
FREE CASH FLOW
Cash From Operating Activities	-$240.8K	-$231.4K	-$757.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48625347	shares
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-714888	usd
CY2022Q3	us-gaap	Cash Cash	123086	usd
CY2021Q4	us-gaap	Cash Cash	828206	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	39754	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	10720	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	181797	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	436405	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	255056	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	324708	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-649854	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	599693	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1600039	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4715936	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30703	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33168	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3096761	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3406714	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	28416	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38692	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127713	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4350695	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	174100	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5720122	usd
CY2022Q3	us-gaap	Goodwill Goodwill	467409	usd
CY2021Q4	us-gaap	Goodwill Goodwill	467409	usd
CY2022Q3	us-gaap	Assets Assets	4350695	usd
CY2021Q4	us-gaap	Assets Assets	5720122	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3868164	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4050798	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1047030	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	907854	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3479762	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62018	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55745	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3008727	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	160509	usd
CY2021Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	126980	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1391506	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1055910	usd
CY2022Q3	STEK	Financing Arrangement FinancingArrangement	239986	usd
CY2021Q4	STEK	Financing Arrangement FinancingArrangement	0	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3433405	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4224585	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8995079	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9387038	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	219465	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71552	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	789566	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119065	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	575740	usd
CY2022Q3	us-gaap	Liabilities Liabilities	9066631	usd
CY2021Q4	us-gaap	Liabilities Liabilities	9725568	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48625347	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48625347	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44685673	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44685673	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	48626	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	44685	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17736628	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10116296	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-673922	usd
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001511820
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	STEK	Shares Issued As Debt Discount Cash Flow SharesIssuedAsDebtDiscountCashFlow		usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21112380	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-172172
	dei	Entity Registrant Name EntityRegistrantName	STEMTECH CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2151440
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10370 USA Today Way
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miramar
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33025
	dei	City Area Code CityAreaCode	(954)
	dei	Local Phone Number LocalPhoneNumber	715-6000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	STEK
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-430255	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21112380	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13086318	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4001048	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3355592	usd
CY2022Q3	STEK	Freight In Costs FreightInCosts	20090	usd
CY2021Q3	STEK	Freight In Costs FreightInCosts	-548	usd
	STEK	Freight In Costs FreightInCosts	46843	usd
	STEK	Freight In Costs FreightInCosts	0	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	180599	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	126432	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	836409	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	575740	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	866431	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	781422	usd
	us-gaap	Gross Profit GrossProfit	2643353	usd
	us-gaap	Gross Profit GrossProfit	2432987	usd
CY2022Q3	STEK	Commission Expenses CommissionExpenses	306293	usd
CY2021Q3	STEK	Commission Expenses CommissionExpenses	133492	usd
	STEK	Commission Expenses CommissionExpenses	761345	usd
	STEK	Commission Expenses CommissionExpenses	375074	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	120434	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	93316	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	400018	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	304276	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3822131	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1290374	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6073133	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3142700	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4248858	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1517182	usd
	us-gaap	Operating Expenses OperatingExpenses	7234496	usd
	us-gaap	Operating Expenses OperatingExpenses	3822050	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3382427	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-735760	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4591143	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1389063	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	18229091	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2710228	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-4112025	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2710228	usd
CY2022Q3	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	126525	usd
CY2021Q3	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	usd
	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	250825	usd
	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	0	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	1833911	usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	7322599	usd
	us-gaap	Interest Expense Other InterestExpenseOther	3004928	usd
	us-gaap	Interest Expense Other InterestExpenseOther	7545189	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9284	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28479	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7333	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38930	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4237648	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3358842	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20768637	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4583892	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3499953	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4873891	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17386210	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5319652	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8091096	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6262954	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	17386210	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-5319652	usd
	us-gaap	Profit Loss ProfitLoss	-8091096	usd
	us-gaap	Profit Loss ProfitLoss	-6262954	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-30707	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10262	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-65034	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-24997	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	17416917	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5309390	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8026062	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6237957	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45588294	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19103079	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44983240	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13259899	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45588294	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19103079	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44983240	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13259899	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	17416917	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5309390	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8026062	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6237957	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	406374	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	477992	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	243667	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	274509	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17010543	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5787382	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8269729	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6512466	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-231943	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	384004	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	242000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	462519	usd
	STEK	Effect Of Reverse Merger Transaction Value EffectOfReverseMergerTransactionValue	1248048	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-274509	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-24997	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6237957	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4432835	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-247927	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	259000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	462518	usd
CY2021Q3	STEK	Effect Of Reverse Merger Transaction Value EffectOfReverseMergerTransactionValue	891218	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-477992	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10262	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5309390	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4432835	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	328388	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2836111	usd
	STEK	Stock Issued During Period Value Of Loan Extension StockIssuedDuringPeriodValueOfLoanExtension	3621774	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	638000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-243667	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-65034	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8026062	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4715936	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28772322	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	110665	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2806111	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	638000	usd
CY2022Q3	STEK	Stock Issued During Period Value Of Loan Extension StockIssuedDuringPeriodValueOfLoanExtension	3321774	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-406374	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-30707	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	17416917	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4715936	usd
	us-gaap	Profit Loss ProfitLoss	-8091096	usd
	us-gaap	Profit Loss ProfitLoss	-6262954	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	330169	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325108	usd
	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	46388	usd
	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	3366	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	328388	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	626004	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2836111	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2400670	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	138897	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-4112025	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2710228	usd
	STEK	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	0	usd
	STEK	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	7179831	usd
	STEK	Gain Loss On Forgiveness Of Ppp Loan GainLossOnForgivenessOfPppLoan	250825	usd
	STEK	Gain Loss On Forgiveness Of Ppp Loan GainLossOnForgivenessOfPppLoan	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3358842	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29034	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13686	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-254608	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-39897	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-69652	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	42092	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	406600	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	256194	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1109	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-10276	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	25169	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-41240	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2380	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	93908	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-976150	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-364823	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	341939	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2638615	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	67228	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	534898	usd
	STEK	Cash Received In Recapitalization Transaction CashReceivedInRecapitalizationTransaction	0	usd
	STEK	Cash Received In Recapitalization Transaction CashReceivedInRecapitalizationTransaction	693	usd
	STEK	Net Proceeds From Financing Arrangement NetProceedsFromFinancingArrangement	239986	usd
	STEK	Net Proceeds From Financing Arrangement NetProceedsFromFinancingArrangement	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	514697	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2104410	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-243667	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-274509	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-705120	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1465078	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	828206	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133065	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	123086	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1598143	usd
	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	53463	usd
	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	0	usd
	STEK	Shares Issued As Debt Discount Cash Flow SharesIssuedAsDebtDiscountCashFlow	462519	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_809_eus-gaap--NatureOfOperations_znvvjI2gd3x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_820_z6W1DkcXNgmg">Organization and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stemtech Corporation and its Subsidiaries (collectively, the “<b>Company</b>”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19<sup>th</sup>, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14<sup>th</sup>, 2022, FINRA gave final approval for said name change, as seen by the 8K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes our products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our Mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Companies subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, OraStem® (Oral Health Care), and D-Fuze™ (Electromagnetic Frequency Blocker).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2021, Stemtech Corporation (“<b>Stemtech</b>”), a (Delaware corporation), entered into a Merger Agreement (the “<b>Merger Agreement</b>”) with Globe Net Wireless Corp. (“<b>Globe Net</b>” or “<b>GNTW</b>”). The merger was accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (ASC 805, Business Combinations). Management evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the merger and concluded, based on a consideration of the pertinent facts and circumstances, that Stemtech acquired Globe Net for financial accounting purposes. On November 9, 2021, the Company changed its fiscal year end date from August 31 to December 31.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“<b>SEC</b>”) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“<b>GAAP</b>”) for complete financial statements. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. All intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements include the accounts of Stemtech Corporation (Parent) and its nine (9) subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">1)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech HealthSciences Corp (U.S.A.) (“Stemtech HealthSciences”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">2)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech Canada, Inc. (Canada)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">3)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech Health Sciences S. de R.L. de C.V. (“Mexico”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">4)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech Services SARL de C.V. (Mexico) (“Stemtech Mexico”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">5)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech Malaysia Holdings Sdn. Bhd. (“Malaysia”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">6)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech Malaysia Sdn. Bhd. (“Malaysia”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">7)<span style="font-family: Times New Roman, Times, Serif"> </span>Stemtech Taiwan Holding, Inc. (“U.S.A.”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">8)<span style="font-family: Times New Roman, Times, Serif"> </span>Tecrecel S.A. (“Ecuador”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">9)<span style="font-family: Times New Roman, Times, Serif"> </span>Food & Health Tech Foodhealth SA (“Ecuador”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The December 31, 2021 consolidated balance sheet included herein was derived from audited consolidated financial statements as of that date. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously filed in its Annual Report on Form 10-K for the year ended December 21, 2021<i>.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	STEK	Working Capital Deficiency WorkingCapitalDeficiency	8400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zddhihlBP2V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zYScrngUN8U8">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	148317	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	249659	usd
CY2022Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	33480	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	186746	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	181797	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	436405	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	3433405	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	1391506	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1275375	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	4224585	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	4886409	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	9789614	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	4112025	usd
	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	363450	usd
CY2022Q3	STEK	Factoring Liability FactoringLiability	239986	usd
CY2021Q4	STEK	Factoring Liability FactoringLiability	0	usd
CY2018Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	150000	usd
CY2019Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267000	usd
CY2022Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2020Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	10664	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2500000	usd
CY2022Q3	STEK	Tax Assessment Amount TaxAssessmentAmount	250000	usd

Files In Submission

Name	View Source	Status
0001683168-22-008016-index-headers.html	Edgar Link	pending
0001683168-22-008016-index.html	Edgar Link	pending
0001683168-22-008016.txt	Edgar Link	pending
0001683168-22-008016-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stek-20220930.xsd	Edgar Link	pending
stemtech_ex3101.htm	Edgar Link	pending
stemtech_ex3102.htm	Edgar Link	pending
stemtech_ex3201.htm	Edgar Link	pending
stemtech_ex3202.htm	Edgar Link	pending
stemtech_i10q-093022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
stek-20220930_cal.xml	Edgar Link	unprocessable
stek-20220930_def.xml	Edgar Link	unprocessable
stek-20220930_lab.xml	Edgar Link	unprocessable
stek-20220930_pre.xml	Edgar Link	unprocessable
stemtech_i10q-093022_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STEK
Stemtech Corp Stock $stek

2022 Q4 Form 10-Q Financial Statement

#000168316822008016 Filed on November 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK Stemtech Corp Stock $stek

2022 Q4 Form 10-Q Financial Statement

#000168316822008016 Filed on November 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK
Stemtech Corp Stock $stek